← All trials
NCT04664738
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 16, 2021
- Primary completion
- Dec 15, 2021
- Completion date
- Mar 15, 2022
- First posted
- Dec 11, 2020
- Last posted
- Nov 15, 2021
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Mayo ClinicLead sponsor
- Mayo ClinicSponsor investigator
- Mayo ClinicOverall official - principal investigator
- Rion LLCCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.